Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX)

Historical Holders from Q4 2020 to Q3 2025

Symbol
TVTX on Nasdaq
CUSIP
89422G107
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
89.4M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
101M
Holdings value
$2.41B
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
233
Number of buys
124
Number of sells
-105
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 11.9% -6.92% $253M -$17.7M 10.6M -6.53% JANUS HENDERSON GROUP PLC Sep 30, 2025
ARMISTICE CAPITAL, LLC 7.52% -24.7% $161M -$51.3M 6.72M -24.2% Armistice Capital, LLC Sep 30, 2025
BlackRock, Inc. 7.5% -21.1% $123M -$24.4M 6.69M -16.6% BlackRock, Inc. Mar 31, 2025
VANGUARD GROUP INC 6.74% +18.2% $88.7M $14.5M 5.99M +19.6% The Vanguard Group Jun 30, 2025
PERCEPTIVE ADVISORS LLC 5.5% $117M 4.9M Perceptive Advisors LLC Oct 6, 2025
MACQUARIE GROUP LTD 5.41% +10.2% $87.9M $9.86M 4.8M +12.6% Macquarie Group Limited Mar 31, 2025
Rock Springs Capital Management LP 3.3% -40.3% $53.5M -$37.6M 2.92M -41.3% Rock Springs Capital Management LP Mar 31, 2025
Woodline Partners LP 2.4% $38.8M 2.11M Woodline Partners LP Dec 31, 2024

Institutional Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 101M $2.41B +$19.8M $23.90 233
2025 Q2 101M $1.49B +$13M $14.80 207
2025 Q1 98M $1.77B +$87.1M $17.92 214
2024 Q4 95.1M $1.66B +$205M $17.42 194
2024 Q3 82.7M $1.16B -$64.9M $13.99 177
2024 Q2 88M $723M +$3.17M $8.22 169
2024 Q1 87.6M $676M +$10.7M $7.71 170
2023 Q4 85.6M $769M +$28.1M $8.99 165
2023 Q3 82.4M $736M -$49.3M $8.94 171
2023 Q2 82.7M $1.27B -$86M $15.36 167
2023 Q1 84.2M $1.89B +$264M $22.49 173
2022 Q4 72.9M $1.53B +$36.5M $21.03 153
2022 Q3 69.7M $1.72B -$12K $24.64 168
2022 Q2 69.5M $1.68B +$17.4M $24.23 166
2022 Q1 69.4M $1.79B +$97.2M $25.77 169
2021 Q4 65.4M $2.03B +$61.5M $31.04 166
2021 Q3 60.8M $1.48B +$4.24M $24.25 145
2021 Q2 60.5M $883M -$73.5M $14.59 131
2021 Q1 62.6M $1.56B +$255M $24.97 147
2020 Q4 52.3M $1.42B +$1.42B $27.26 136